Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Verve Therapeutics, Inc. - Common Stock (NQ:VERV)

11.18 +0.08 (+0.68%)
Streaming Delayed Price Updated: 12:25 PM EDT, Jul 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,584,080
Open 11.14
Bid (Size) 11.17 (46)
Ask (Size) 11.18 (685)
Prev. Close 11.10
Today's Range 11.10 - 11.24
52wk Range 2.865 - 11.40
Shares Outstanding 61,930,485
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Bullish Biotech Stocks With Explosive Growth Trends
These small-cap biotech stocks offer high-reward potential with bullish momentum and key catalysts ahead in urology, autoimmune, and gene editing therapies 
Via MarketBeat
Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook
Goldman Sachs raised its year-end S&P 500 forecast and identified three stocks that are poised to outperform in the second half of 2025: KSS, NTLA, and GOGO. 
Via MarketBeat
Topics Economy Stocks

Performance

YTD
+85.9%
+85.9%
1 Month
+0.6%
+0.6%
3 Month
+104.3%
+104.3%
6 Month
+43.3%
+43.3%
1 Year
+45.1%
+45.1%

More News

Read More
VERVE THERAPEUTICS INC (NASDAQ:VERV) - A High-Growth Biotech Stock Meeting Minervini's Criteria
Via Chartmill
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (Nasdaq - VERV), Sage Therapeutics, Inc. (Nasdaq - SAGE), Cantaloupe, Inc. (Nasdaq - CTLP), Volato Group, Inc. (NYSE American - SOAR)
From Brodsky & Smith LLC
Via GlobeNewswire
Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week
Via The Motley Fool
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTLP, VERV, CVAC on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc. - VERV
From Kahn Swick & Foti, LLC
Via Business Wire
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst
Via Benzinga
This Verve Therapeutics Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Wednesday
Via Benzinga
Market Monitor News June 18 (Jabil, Reddit & Verve Therapeutics UP - Solar Stocks First Solar, Sunrun & SolarEdge DOWN)
Via Chartmill
5 Analysts Assess Verve Therapeutics: What You Need To Know
Via Benzinga
These stocks are moving in today's session
Via Chartmill
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VERV, SAGE, CTLP, SOAR on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Which stocks are moving on Tuesday?
Via Chartmill
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (Nasdaq - VERV), Sage Therapeutics, Inc. (Nasdaq - SAGE), Cantaloupe, Inc. (Nasdaq - CTLP), Volato Group, Inc. (NYSE American - SOAR)
From Brodsky & Smith LLC
Via GlobeNewswire
VERV Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Verve Therapeutics, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Why Verve Therapeutics Stock Is Skyrocketing Today
Via The Motley Fool
Jabil Posts Upbeat Earnings, Joins Verve Therapeutics, John Wiley & Sons And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Which stocks are gapping on Tuesday?
Via Chartmill
Power Metallic (TSX.V: PNPN) Secures Largest Saudi License Amid June 2025 Gold Surge – Material Gains & More Stocks Inside
Via AB Newswire
Verve Therapeutics Stock Rockets 75% Pre-Market After Eli Lilly Agrees To Acquire The Company For Up To $1.3B: Retail Says Offer Is ‘Low’
Via Stocktwits
Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover
Via Investor's Business Daily
Top 3 Health Care Stocks That Are Ticking Portfolio Bombs
Via Benzinga
Get insights into the top gainers and losers of Tuesday's pre-market session.
Via Chartmill

Frequently Asked Questions

Is Verve Therapeutics, Inc. - Common Stock publicly traded?
Yes, Verve Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Verve Therapeutics, Inc. - Common Stock trade on?
Verve Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Verve Therapeutics, Inc. - Common Stock?
The ticker symbol for Verve Therapeutics, Inc. - Common Stock is VERV on the Nasdaq Stock Market
What is the current price of Verve Therapeutics, Inc. - Common Stock?
The current price of Verve Therapeutics, Inc. - Common Stock is 11.18
When was Verve Therapeutics, Inc. - Common Stock last traded?
The last trade of Verve Therapeutics, Inc. - Common Stock was at 07/24/25 12:25 PM ET
What is the market capitalization of Verve Therapeutics, Inc. - Common Stock?
The market capitalization of Verve Therapeutics, Inc. - Common Stock is 692.07M
How many shares of Verve Therapeutics, Inc. - Common Stock are outstanding?
Verve Therapeutics, Inc. - Common Stock has 692M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.